Royalty Pharma Surges to 488th in Trading Volume with 1.99 Billion Turnover

On May 7, 2025, Royalty Pharma (RPRX) saw a significant surge in trading volume, with a total turnover of 1.99 billion, marking a 31.35% increase from the previous day. This surge placed Royalty Pharma at the 488th position in terms of trading volume for the day.

Royalty Pharma is anticipated to release its first-quarter 2025 earnings report before the market opens on May 8, 2025. Analysts project that the company will report earnings of $1.02 per share and revenue of $724.69 million for the quarter. The company's previous earnings report, released on February 11, 2025, showed earnings per share of $1.15, surpassing analysts' estimates of $0.99 by $0.16. Royalty Pharma has a return on equity of 24.40% and a net margin of 37.94%.

Royalty Pharma recently declared a quarterly dividend of $0.22 per share, payable on June 10, 2025. Investors of record as of May 16, 2025, will receive this dividend. This represents an annualized dividend of $0.88 and a dividend yield of 2.74%. The company's dividend payout ratio is 60.69%.

Citigroup recently reaffirmed a "buy" rating on Royalty Pharma shares. One analyst has given the stock a "hold" rating, four have assigned a "buy" rating, and one has given a "strong buy" rating. The average rating for the stock is "Buy," with an average price target of $42.50.